Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Comparative, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Phase 2a Study of the Safety and Efficacy of CMX-2043 for Periprocedural Injury Protection in Subjects Undergoing Coronary Angiography at Risk of Radio-contrast Induced Nephropathy (CARIN)

NCT02103959 is registered in ClinicalTrials.gov with Ischemix, LLC as lead sponsor.

NCT NCT02103959
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02103959 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Comparative, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Phase 2a Study of the Safety and Efficacy of CMX-2043 for Periprocedural Injury Protection in Subjects Undergoing Coronary Angiography at Risk of Radio-contrast Induced Nephropathy (CARIN)
Lead sponsor
Ischemix, LLC
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2014
Completion date
December 31, 2015
Enrollment
361 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non stemi, unstable angina